• China Supply Medical Glucose Injection 10% with GMP Shinepharm
  • China Supply Medical Glucose Injection 10% with GMP Shinepharm
  • China Supply Medical Glucose Injection 10% with GMP Shinepharm
  • China Supply Medical Glucose Injection 10% with GMP Shinepharm
  • China Supply Medical Glucose Injection 10% with GMP Shinepharm
  • China Supply Medical Glucose Injection 10% with GMP Shinepharm

China Supply Medical Glucose Injection 10% with GMP Shinepharm

Application: Human
Usage Mode: I.V.
Suitable for: Elderly, Children, Adult
State: Liquid
Shape: Liquid
Type: Biological Products
Samples:
US$ 0/Bottle 1 Bottle(Min.Order)
| Request Sample
Customization:

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Manufacturer/Factory, Trading Company

Basic Info.

Model NO.
AMC15003-04
Pharmaceutical Technology
Cp, Bp
Shelf Life
3 Years
Specificatio
10%, 500ml
Documents
GMP, Copp, Ctd
Delivery Time
30~60 Days
Transport Package
1bottle/ Box, 30boxes/CTN
Specification
10%, 500ML
Trademark
Shinepharm
Origin
China
Production Capacity
100000ctns Per Month

Product Description

 

China Supply Medical Glucose Injection 10% with GMP Shinepharm

Indications

10% glucose solution is indicated for supplemental intravenous nutrition as a preferred source of carbohydrate.

Dosage and Administration

Usage: Intravenous Infusion. 

Dosage: There is no recommended dose. The volume of 10% glucose solution needed as supplemental nutrition will vary with patient age, body weight, complementary treatment and severity of the clinical condition.

Precautions & Warning:

1.Do not use after date of expiry printed on the bag.

2. Infusion rate should be sufficiently slow to allow detection of osmotic diuresis - Glucose infusions are incompatible with blood for transfusion as haemolysis and clumping may occur; do not administer through the same infusion equipment as blood or blood components for transfusion (either before, during or after their administration).

3. If more than 180g glucose is given per day (equivalent to 1.8 litres) frequent monitoring of blood glucose is required and insulin may be necessary.

4. Prior to and during infusion serum and/or urinary electrolytes and glucose should be monitored to assess the nature and severity of fluid depletion and electrolyte imbalance.

5. Use with caution in severe malnutrition (when glucose infusion can cause sodium retention, oedema and heart failure), and in thiamine deficiency.

6. Glucose intravenous infusions are usually isotonic solutions. In the body, however, glucose containing fluids can become extremely physiologically hypotonic due to rapid glucose metabolization .

7. Depending on the tonicity of the solution, the volume and rate of infusion and depending on a patient's underlying clinical condition and capability to metabolize glucose, intravenous administration of glucose can cause electrolyte disturbances most importantly hypo- or hyperosmotic hyponatraemia.

Contraindications:

Conditions of water excess. The use of hyperosmotic glucose solutions is contraindicated in patients with anuria, intracranial or intraspinal haemorrhage, and in delirium tremens where there is dehydration.

Hyperglycaemia resulting from infusion with glucose solutions following acute ischaemic stroke is implicated in increasing cerebral ischaemic brain damage and impaired recovery.

Adverse Reactions:

1.Hypertonic glucose solutions may have a low pH and may cause venous irritation, local pain and thrombophlebitis. Intravenous infusion of glucose solutions can lead to the development of fluid and electrolyte disturbances including hypokalaemia, hypomagnesaemia and hypophosphataemia.

Hypokalaemia may complicate glucose infusions, especially when combined with insulin in the treatment of diabetic ketoacidosis.

Hypophosphataemia may occur if glucose is used as a feed without added phosphate.

2.Metabolism and nutrition disorders: Hospital Acquired Hyponatraemia* (frequency not known).

3.Nervous system disorders: Hyponatraemic encephalopathy* (frequency not known). * Hospital acquired hyponatraemia may cause irreversible brain injury and death due to development of acute hyponatraemic encephalopathy .

4.In the event of adverse reaction stop infusion immediately.

Drug interactions:

1.Drugs leading to an increased vasopressin effect.

2.Drugs stimulating vasopressin release.

3.Drugs potentiating vasopressin action.

4.Other medicinal products increasing the risk of hyponatraemia also include diuretics in general and antiepileptics such as oxcarbazepine.

5.Confirm additive compatibility before use.

Storage instructions:

Do not store above 30° C. Do not freeze. Store in the original outer container.

label: Regulating water, electrolyte and acid-base balance
China Supply Medical Glucose Injection 10% with GMP Shinepharm

China Supply Medical Glucose Injection 10% with GMP ShinepharmChina Supply Medical Glucose Injection 10% with GMP ShinepharmChina Supply Medical Glucose Injection 10% with GMP ShinepharmChina Supply Medical Glucose Injection 10% with GMP ShinepharmChina Supply Medical Glucose Injection 10% with GMP ShinepharmChina Supply Medical Glucose Injection 10% with GMP Shinepharm

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Manufacturer/Factory, Trading Company
Management System Certification
ISO 9001, GMP, ISO 13485, FSC
Import & Export Mode
Have Own Export License